Literature DB >> 6777263

Use of oral sodium cromoglycate in persistent diarrhoea.

T D Bolin.   

Abstract

Twenty patients with persistent diarrhoea participated in a randomised, double-blind trial of oral sodium cromoglycate and placebo. Eight patients noted significant improvement in their diarrhoea while taking sodium cromoglycate and this did not correlate with the presence of other atopic diseases, a history of food intolerance, or the presence of lactase deficiency. The results suggest that some patients with diarrhoea of unknown cause may have food allergy as a major contributing cause for their diarrhoea.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6777263      PMCID: PMC1419375          DOI: 10.1136/gut.21.10.848

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  7 in total

1.  Disodium cromoglycate in gastrointestinal protein intolerance.

Authors:  S Freier; H Berger
Journal:  Lancet       Date:  1973-04-28       Impact factor: 79.321

2.  Immune complexes containing food proteins in normal and atopic subjects after oral challenge and effect of sodium cromoglycate on antigen absorption.

Authors:  R Paganelli; R J Levinsky; J Brostoff; D G Wraith
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

3.  Letter: Treatment of allergy to cow's milk.

Authors:  J A Kuzemko; K R Simpson
Journal:  Lancet       Date:  1975-02-08       Impact factor: 79.321

4.  Oral cromoglycate in treatment of adverse reactions to foods.

Authors:  G A Vaz; L K Tan; J W Gerrard
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

5.  The effect of orally administered sodium cromoglycate on symptoms of food allergy.

Authors:  A Dannaeus; T Foucard; S G Johansson
Journal:  Clin Allergy       Date:  1977-03

6.  Oral cromolyn therapy in patients with food allergy: a preliminary report.

Authors:  R M Nizami; P K Lewin; M T Baboo
Journal:  Ann Allergy       Date:  1977-08

7.  Production of IgE complexes by allergen challenge in atopic patients and the effect of sodium cromoglycate.

Authors:  J Brostoff; C Carini; D G Wraith; P Johns
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

  7 in total
  8 in total

1.  Mast cells and intestinal motility disorders (mastocytic enteritis/colitis).

Authors:  David F Schaeffer; Richard Kirsch; Robert H Riddell
Journal:  Dig Dis Sci       Date:  2012-05       Impact factor: 3.199

Review 2.  Food allergy in irritable bowel syndrome: The case of non-celiac wheat sensitivity.

Authors:  Pasquale Mansueto; Alberto D'Alcamo; Aurelio Seidita; Antonio Carroccio
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

Review 3.  Functional diarrhoea.

Authors:  A T Axon
Journal:  Int J Colorectal Dis       Date:  1986-01       Impact factor: 2.571

4.  Determination of the antiulcer properties of sodium cromoglycate in pylorus-ligated albino rats.

Authors:  Vivek Srivastava; A H M Viswanathaswamy; Govind Mohan
Journal:  Indian J Pharmacol       Date:  2010-06       Impact factor: 1.200

5.  Antidiarrhoeal agents. Clinical pharmacology and therapeutic use.

Authors:  M J Bradshaw; R F Harvey
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

6.  Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate.

Authors:  O Leri; S Tubili; F G De Rosa; M A Addessi; G Scopelliti; W Lucenti; D De Luca
Journal:  Inflammopharmacology       Date:  1997       Impact factor: 4.473

Review 7.  Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.

Authors:  Theodor Bokic; Martin Storr; Rudolf Schicho
Journal:  Pharmacology       Date:  2015-07-01       Impact factor: 2.547

8.  The immune system in irritable bowel syndrome.

Authors:  Giovanni Barbara; Cesare Cremon; Giovanni Carini; Lara Bellacosa; Lisa Zecchi; Roberto De Giorgio; Roberto Corinaldesi; Vincenzo Stanghellini
Journal:  J Neurogastroenterol Motil       Date:  2011-10-31       Impact factor: 4.924

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.